GSA Capital Partners’s Aerie Pharmaceuticals AERI Stock Holding History

GSA Capital Partners’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-23,006	Closed	-$311K	–	1259
2020 Q1	$311K	Buy	+23,006	New	+$436K	0.08%	461
2019 Q4	–	Sell	-12,309	Closed	-$237K	–	1827
2019 Q3	$237K	Sell	12,309 -11,900	-49%	-$273K	0.03%	1083
2019 Q2	$715K	Buy	+24,209	New	+$933K	0.08%	439
2018 Q4	–	Sell	-6,000	Closed	-$369K	–	1858
2018 Q3	$369K	Buy	+6,000	New	+$386K	0.02%	1225
2018 Q1	–	Sell	-16,400	Closed	-$980K	–	1893
2017 Q4	$980K	Buy	16,400 +9,956	+155%	+$604K	0.06%	605
2017 Q3	$313K	Buy	6,444 +1,538	+31%	+$83.9K	0.02%	1217
2017 Q2	$258K	Buy	+4,906	New	+$228K	0.02%	1368
2016 Q3	–	Sell	-12,437	Closed	-$219K	–	2034
2016 Q2	$219K	Buy	+12,437	New	+$201K	0.01%	1529
2015 Q4	–	Sell	-41,248	Closed	-$732K	–	2021
2015 Q3	$732K	Buy	+41,248	New	+$747K	0.04%	874

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

GSA Capital Partners's AERI Position: Q2 2020 in Review

GSA Capital Partners sold out of Aerie Pharmaceuticals (AERI) in Q2 2020, closing a stake of 23,006 shares — an estimated $311K sold.

GSA Capital Partners first reported a position in AERI in Q3 2015 and held it in 9 quarters. The position peaked at $980K in Q4 2017. 155 funds tracked by Wall St. Rank hold AERI as of Q2 2020.

GSA Capital Partners reported no remaining Aerie Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
GSA Capital Partners sold 23,006 Aerie Pharmaceuticals shares in Q2 2020, an estimated $311K.
GSA Capital Partners first reported a position in Aerie Pharmaceuticals in Q3 2015 and held it in 9 quarters.
GSA Capital Partners's Aerie Pharmaceuticals position peaked at $980K in Q4 2017.
155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2020.

Based on GSA Capital Partners's 13F filing for Q2 2020, filed 11 Aug 2020.